Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optim-PRE
NCT07665853Phase 3Not yet recruiting
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Jul 2026
- Primary completion
- May 2028
- Countries
- 7
01
Overview
A Phase 3 trial of aspirin in preeclampsia, sponsored by Vall d'Hebron Research Institute. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
aspirin
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT07665853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07665853.